Michiel Van De Sande, MD, PhD, Leiden University Medical Center, Leiden, Netherlands, discusses the current obstacles when it comes to predicting overall survival (OS) and disease recurrence in patients with severe comorbidities in addition to soft tissue sarcoma. Prof. Van De Sande expresses that future advancements of this model should consider the presence of comorbidities to ascertain better survival estimates as well as the importance of quality of life estimates following a particular course of therapy. This interview took place at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.